Lord, Abbett & Co’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.3M Buy
+729,423
New +$18.2M 0.05% 324
2025
Q1
– Sell
-437,772
Closed -$8.25M – 569
2024
Q4
$8.25M Buy
437,772
+87,132
+25% +$2M 0.03% 406
2024
Q3
$7.88M Buy
+350,640
New +$7.94M 0.03% 427

Other funds holding NRIX

Lord, Abbett & Co's NRIX Position: Q3 2026 in Review

Lord, Abbett & Co opened a new position in Nurix Therapeutics (NRIX) in Q3 2026: 729,423 shares worth $17.3M. The stake represents 0.05% of the portfolio and ranks #324 among its holdings. This is a return to the name: Lord, Abbett & Co previously reported a position in NRIX as recently as Q4 2024.

Lord, Abbett & Co first reported a position in NRIX in Q3 2024 and has held it in 3 quarters since. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Lord, Abbett & Co held 729,423 shares of Nurix Therapeutics worth $17.3M as of Q3 2026.
  • Nurix Therapeutics was a new Lord, Abbett & Co position in Q3 2026.
  • Nurix Therapeutics made up 0.05% of Lord, Abbett & Co's portfolio in Q3 2026, its #324 holding.
  • Lord, Abbett & Co first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 3 quarters since.
  • 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.